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ABSTRACT
Introduction: Optic neuritis leads to degeneration of
retinal ganglion cells whose axons form the optic
nerve. The standard treatment is a methylprednisolone
pulse therapy. This treatment slightly shortens the time
of recovery but does not prevent neurodegeneration
and persistent visual impairment. In a phase II trial
performed in preparation of this study, we have shown
that erythropoietin protects global retinal nerve fibre
layer thickness (RNFLT-G) in acute optic neuritis;
however, the preparatory trial was not powered to
show effects on visual function.
Methods and analysis: Treatment of Optic Neuritis
with Erythropoietin (TONE) is a national, randomised,
double-blind, placebo-controlled, multicentre trial with
two parallel arms. The primary objective is to
determine the efficacy of erythropoietin compared to
placebo given add-on to methylprednisolone as
assessed by measurements of RNFLT-G and low-
contrast visual acuity in the affected eye 6 months after
randomisation. Inclusion criteria are a first episode of
optic neuritis with decreased visual acuity to ≤0.5
(decimal system) and an onset of symptoms within
10 days prior to inclusion. The most important
exclusion criteria are history of optic neuritis or
multiple sclerosis or any ocular disease (affected or
non-affected eye), significant hyperopia, myopia or
astigmatism, elevated blood pressure, thrombotic
events or malignancy. After randomisation, patients
either receive 33 000 international units human
recombinant erythropoietin intravenously for 3
consecutive days or placebo (0.9% saline)
administered intravenously. With an estimated power of
80%, the calculated sample size is 100 patients. The
trial started in September 2014 with a planned
recruitment period of 30 months.
Ethics and dissemination: TONE has been approved
by the Central Ethics Commission in Freiburg (194/14)
and the German Federal Institute for Drugs and
Medical Devices (61-3910-4039831). It complies with
the Declaration of Helsinki, local laws and ICH-GCP.
Trial registration number: NCT01962571.
INTRODUCTION
Background and trial rationale
Optic neuritis (ON) is one of the most
common manifestations of multiple sclerosis
(MS) and leads to neurodegeneration in the
optic nerve and the retina causing persistent
visual impairment. Methylprednisolone pulse
therapy is the standard treatment for acute
Strengths and limitations of this study
▪ This study examines a potentially neuroprotective
agent in optic neuritis, a disease with clearly
defined kinetics of neurodegeneration.
▪ We assess potential neuroprotective effects of
erythropoietin by combining a multitude of com-
plementary morphological and functional
measures.
▪ Retinal nerve fibre layer degeneration correlates
with general brain atrophy in multiple sclerosis;
therefore, the results of the study are meaningful
for multiple sclerosis in general.
▪ The dosage of erythropoietin was chosen
according to a prior phase II trial without having
performed a proper dose-finding study.
▪ In order to start treatment as soon as possible,
we do not distinguish between possible subtypes
of optic neuritis at the time of inclusion.
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ON. Although it accelerates visual recovery, it does not
inﬂuence visual outcome, lesion length or atrophy of
the optic nerve.1 In an animal model of ON, methyl-
prednisolone even increased retinal ganglion cell degen-
eration by inhibition of a neurotrophin-dependent
pathway.2 Data from animal models of ON indicate that
the downstream mechanisms of neurodegeneration
involve pathways regulated by neurotrophins.3
Erythropoietin (EPO) has shown neurotrophin-like
properties in models of ischaemia, trauma, epilepsy and
MS.4 In contrast to ‘classical’ neurotrophins, EPO can
be administered systemically. In an animal model of ON,
EPO was particularly effective when given in combin-
ation with methylprednisolone.5 Encouraged by these
results, a phase II pilot trial was conducted in patients
presenting with ON as a ﬁrst clinical event indicative of
MS.6 In the EPO treatment group, a signiﬁcant protec-
tion of the retinal nerve ﬁbre layer (RNFL) was deter-
mined by optical coherence tomography (OCT).
Clinical evidence for optic nerve neuroprotection by EPO
Diem et al6 have performed a pilot randomised clinical
trial in preparation to this phase III trial (VISION
PROTECT, NCT00355095): 40 patients were assigned to
receive either 33 000 international units (IU) EPO or
placebo intravenous injections per day for 3 days in add-
ition to methylprednisolone pulse therapy. Safety moni-
toring revealed no speciﬁc issues. Thirty-seven patients
(20/17 EPO/placebo) were analysed for the primary
end point change in retinal nerve ﬁbre layer thickness
(RNFLT) according to the intention-to-treat analysis. In
patients treated with EPO, RNFLT decreased by a mean
of 7.5 μm at week 16 compared to a mean of 16.0 μm in
the placebo group (p=0.03), measured with time-
domain OCT. Decrease in retrobulbar diameter of the
optic nerve was smaller in the EPO group (p=0.01),
determined by MRI. Testing of visual functions revealed
trends towards an improved outcome after EPO treat-
ment. The trial regimen chosen in TONE has been
adapted from VISION PROTECT, which revealed that
the general design is feasible and the chosen outcome
measures are adequate.
Risk–benefit assessment
In general, EPO will not be administered beyond 3 days
because neuronal damage in ON is considered to be an
acute event. In a schizophrenia trial, 40 000 IU of EPO
were given weekly over 3 months resulting in a need for
bloodlettings in 8 of 39 patients.7 In contrast, the treat-
ment over 3 days in the pilot trial VISION PROTECT
did not lead to any clinically relevant increases in red
blood cell counts.6
The majority of recorded adverse events in our pilot
study6 consisted of side effects associated with methyl-
prednisolone such as hot ﬂushes, facial ﬂushing, mood
changes or hyperglycaemia and did not occur more fre-
quently in EPO-treated patients. Five of 40 patients com-
plained of headache during the treatment period, 4 of
whom had received EPO. Four serious adverse events
were recorded throughout the study but were judged as
unrelated to the study medication. Haemoglobin values
showed a transient slight increase in the EPO-treated
group after 1 week. Blood pressure after treatment with
EPO remained stable during the treatment period and
did not differ from values after methylprednisolone
administration alone. Possible additional side effects—
although not reported in the pilot study—include
increases in red blood cell and thrombocyte counts, ele-
vations of blood pressure and thromboembolic compli-
cations.8 Since the risk of these events might especially
be increased if EPO is combined with methylpredniso-
lone, we exclude patients with vascular risk factors.
Other exclusion criteria of our study such as history of
malignancy or epilepsy are also explained by the spec-
trum of undesired effects of EPO.8 Professional or semi-
professional sports activities belong to the exclusion
criteria because EPO has been misused for doping, espe-
cially to enhance endurance of elite cyclists.9
Additionally, pure red cell aplasia has been described as
a rare but potentially fatal side effect of EPO. It is
caused by neutralising antibodies induced by repetitive
exposure to subcutaneous but eventually also intraven-
ous EPO formulations.10 For this reason, we included
monitoring of antibodies against EPO into our safety
assessment.
METHODS AND ANALYSIS
Study design
The study is designed as a prospective, double-blind,
randomised controlled trial with participating depart-
ments located at German University Medical Centers.
The trial has two parallel arms, one with an injection of
33 000 IU human recombinant EPO per day for 3 con-
secutive days, and the other with placebo administered
in an equal fashion. In both arms, patients will receive
1000 mg of methylprednisolone intravenously per day
for 3 days according to the standard of care.11 A 1:1 allo-
cation ratio is applied to ensure equally sized treatment
groups. The trial is registered at http://www.
clinicaltrials.gov (NCT01962571) and http://www.
germanctr.de (DRKS00005298).
Primary objective
Determination of the efﬁcacy of EPO compared to
placebo given as add-on to methylprednisolone (stand-
ard of care) as assessed by measurements of global
RNFLT-G and low-contrast visual acuity (LCVA) in the
affected eye 6 months after randomisation.
Setting
Participating trial sites are the University Medical
Centers in Berlin, Bonn, Düsseldorf, Erlangen, Essen,
Freiburg, Göttingen, Hamburg, Hannover, Heidelberg,
Mainz, Munich (LMU/TUM) and Tübingen.
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Population
Patients with acute ON are going to be enrolled in this
trial. For diagnosis of ON, the recent consensus diagnos-
tic ﬂow chart published by Petzold et al12 is followed.
Patients are only eligible if they provide written
informed consent and if the investigator has veriﬁed
that they meet all of the inclusion criteria and none of
the exclusion criteria. Patients of both genders will be
enrolled as the results of the preclinical and clinical
studies did not indicate any gender effect on the trial
treatment in terms of efﬁcacy and safety. Inclusion and
exclusion criteria are shown in box 1.
Treatment
Experimental intervention
A total of 33 000 IU human recombinant EPO given as a
bolus injection (epoetin alfa, Hexal AG, Holzkirchen,
Germany) per day intravenously on days 1, 2 and 3 in
addition to standard methylprednisolone (1000 mg/day
intravenously on days 1, 2 and 3).
Control intervention
Placebo (0.9% saline) administered intravenously on
days 1, 2 and 3 in addition to standard methylpredniso-
lone (1000 mg/day intravenously on days 1, 2 and 3).
Visit schedule
Following randomisation and initiation of trial treatment
(visit 1), the patient should be admitted to the ward at
the trial site from days 1 to 3. If this is not possible for
logistical reasons, assessments may be carried out on an
outpatient basis at the discretion of the investigator. The
following visits at weeks 1, 4, 16 and 26 and month 24
will be performed in the outpatient setting. Table 1
shows the schedule of visits. In case of pregnancy,
regular follow-up visits will be performed if possible. If
pregnancy occurs during the ﬁrst 3 months after study
medication, the treating gynaecologist will be informed
to decide about an intensiﬁed pregnancy observation.
Outcome measures
Primary end point
TONE has two primary end points, which will be tested
in a hierarchical manner. The ﬁrst is the mean (global)
RNFLT of all retinal segments along a circle of 12°, that
is, 3.5 mm diameter (RNFLT-G-12) of the fellow eye at
baseline minus RNFLT-G-12 of the affected eye 6 months
after randomisation.13 RNFLT became a standard
measure for neurodegeneration over the recent
years.13 14 Using time-domain OCT, thinning of the
RNFL from 100 to 78 µm (means, p=0.0001) was seen in
the majority of ON patients (74%) within 6 months.15
RNFLT decline reaches a plateau around 4 months.13
Several investigations have established that RNFLT meas-
urement by OCT is a robust tool for the quantiﬁcation
of optic nerve axons and the degree of optic nerve
atrophy, especially after ON.16–19 The recent introduc-
tion of the spectral-domain OCT technique allows for
more precise quantiﬁcation of the RNFL, in particular
using the Spectralis system which incorporates eye track-
ing for better retest variability (variation coefﬁcient of
0.6%20 compared with 5% using time-domain OCT).21
RNFLT will be determined along a ring of 3.5 mm
(approximately 12°) diameter concentrically centred on
the Bruch’s membrane opening at the optic disc using
the Spectralis OCT (Heidelberg Engineering,
Heidelberg, Germany). RNFLT has been employed as a
primary outcome measure in VISION PROTECT and in
ongoing trials NCT01451593 and NCT01073813 and has
been recommended as such in the literature.13 17
The second primary outcome measure is LCVA in
the affected eye 6 months after randomisation. While
high-contrast visual acuity (HCVA) recovers well after
ON,11 LCVA is most likely to remain subnormal: 22%
of cases with fully recovered HCVA revealed subnormal
LCVA.22 LCVA correlates well with health-related
quality of life23 and correlates signiﬁcantly with
RNFLT24 in patients with MS after previous ON. LCVA
will be recorded by 2.5% low-contrast Sloan letter
charts.24
Secondary objectives and end points
In addition to the primary objective, seven OCT analyses
will be performed to increase the likelihood of captur-
ing neuroprotective properties:
1. RNFLT in the papillomacular bundle
(RNFLT-PMB-12) fellow eye at baseline minus
RNFLT-PMB-12 of the affected eye 6 months after
randomisation;
2. RNFLT in the temporal quadrant (RNFLT-T-12)
fellow eye at baseline minus RNFLT-T-12 of the
affected eye 6 months after randomisation;
3. RNFLT-G-12 of the affected eye 6 months after
randomisation;
4. RNFLT-PMB-12 of the affected eye 6 months after
randomisation;
5. RNFLT-T-12 of the affected eye 6 months after
randomisation;
6. Total macular volume (TMV) in the fellow eye at
baseline minus TMV of the affected eye 6 months
after randomisation;
7. TMV of the affected eye 6 months after
randomisation.
In addition to these standardised OCT parameters,
the Bern Photographic Reading Center will perform
further analyses of manually segmented retinal layers
(eg, thickness of RNFL plus inner nuclear layer).
The functional end points HCVA and contrast sensitiv-
ity will be assessed using standard Early Treatment
Diabetic Retinopathy Study charts (ETDRS charts) and
Mars charts, respectively.25 The visual ﬁeld will be
recorded on automated, static perimeters (Octopus 900
perimeter, Haag-Streit, Köniz, Switzerland) using the
newly developed German Adaptive Threshold
Estimation (GATE) strategy within the entire 30° visual
ﬁeld in a (fast) threshold determining manner26 and
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analysed centrally by the Center of Competence ‘Vision
Research’ of the Aalen University, Germany.
Neurological examinations will be performed at each
visit to assess the Extended Disability Status Score
(EDSS), an international standard neurological
symptom severity classiﬁcation system. Amplitudes and
latencies of visual evoked potentials will be measured by
standard electrophysiological equipment in accordance
with the recommendation of the International Society
for Clinical Electrophysiology. Quality of life will be
assessed using the validated German version of 25-item
National Eye Institute Visual Functioning Questionnaire
(Interviewer Version).27 Its overall score will be analysed.
This questionnaire proved to be sensitive to chronic eye
disease including ON.23 24
In addition, relapse rates of ON and/or MS will be
documented and analysed. Safety will be evaluated in
terms of adverse events, serious adverse events and
laboratory data (haemoglobin, EPO antibodies).
Sample size
Sample size calculations are based on RNFLT-G-12. For the
second primary end point LCVA, power calculations with
the resulting sample size have been performed. The
primary analysis will be performed applying a linear
regression model for the primary end point (RNFLT-G-12
of the contralateral healthy eye at baseline minus
RNFLT-G-12 in the affected eye 6 months after randomisa-
tion) with RNFLT-G-12 of the contralateral healthy eye at
baseline as a covariate. The resulting treatment estimate is
identical to the treatment estimate resulting from a linear
regression model with the same covariates, but using
RNFLT-G-12 in the affected eye 6 months after randomisa-
tion instead as the dependent variable. Therefore, the fol-
lowing calculations based on the end point RNFLT-G-12 in
the affected eye 6 months after randomisation are valid
considerations for the required sample size. The sample
size revision planned after 50 patients will use the SD of
the primary end point.
Box 1 Inclusion and exclusion criteria
Inclusion criteria
1. Written informed consent obtained according to international guidelines and local laws
2. Male and female patients aged ≥18 to ≤50 years
3. Patients with optic neuritis (ON)
4. First symptoms of ON ≤10 days prior to the first administration of investigational product
5. High-contrast visual acuity (HCVA) of 0.5 (decimal system) corresponding to a minimum angle of resolution (MAR) of 2.0, a logMAR
value of 0.3, or a Snellen equivalent of 6/12 (UK notation) and 20/40 (UK notation)12
6. Adequate optical coherence tomography (OCT) measurements available (according to quality control by Bern Photographic Reading
Center)
Exclusion criteria
1. Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial
2. Simultaneous participation in another interventional trial which could interfere with this trial and/or participation in a clinical trial within
the last 3 months before enrolment in this trial
3. Refractive anomalies: hyperopia >5 dpt, myopia <−7 dpt, astigmatism >3 dpt
4. Media opacity
5. Severe papillitis
6. Previous ON
7. Any other optic nerve and retinal disease
8. Pre-existing multiple sclerosis (MS) diagnosed according to the 2005 or 2010 McDonald criteria,35 36 or any other neurological disease
9. Congenital diseases (thrombophilia, phenylketonuria)
10. Acquired diseases (autoimmune diseases, cardiovascular diseases, diabetes mellitus, uncontrolled hypertension, any malignancy, epi-
lepsy, known tuberculosis with ongoing or unknown activity, acute gastrointestinal ulceration within the past 3 months prior to random-
isation, acute viral, bacterial or fungal infection, known infection with HIV, hepatitis B virus, or hepatitis C virus, history of colitis
ulcerosa, diverticulitis, or acute enteroanastomosis, known osteoporosis, history of thromboembolic events, elevated haemoglobin level,
polycythaemia, any other significant illness potentially interfering with any trial assessment or trial treatment)
11. Performing semiprofessional or professional sporting activities or physical training
12. Pretreatment with corticosteroids in the last 30 days prior to the onset of optic neuritis
13. Pretreatment with erythropoietin (EPO)
14. Known or persistent abuse of medication, drugs or alcohol
15. Active immunisation within 2 weeks prior to randomisation
16. Significant surgery within 4 weeks prior to randomisation
17. Blood donation or bloodletting within 4 weeks prior to screening
18. Pretreatment with immunosuppressive or immunomodulatory agents
19. Persons who are in a relationship of dependence/employment with the sponsor or the investigator
20. Female patients: pregnancy, planned pregnancy within the next 3 months or lactation period
21. Female patients: inability or unwillingness to use two effective methods of contraception (barrier methods, hormonal methods or abstin-
ence) during the initial 3 months of the study
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Table 1 Visit schedule
Action
Screening/
baseline day 0
(−3 days)
Therapy day
1
Therapy day
2
Therapy day
3
Week 1
(±4 days)
Week 4
(±4 days)
Week 16
(±4 days)
Week 26
(±7 days)
Month 24
(±7 days)
Informed consent X
Demographics X
Inclusion/exclusion criteria X
Medical history X
Present complaints X X X X X X X X X
MS relapse/ON
recurrence
X X X X
Concomitant medication X X X X X X X X X
Physical examination X* X* X*
Vital signs† X 3 X 3 X 3 X X X
Body weight X* X* X*
ECG X* X*
Routine laboratory‡ X X X X
Urinalysis (if clinically
indicated)
X* (X*) (X*) (X*) (X*)
Pregnancy test X*
EPO antibodies (analysis
in central lab)
X X
Aquaporin 4 antibodies X
Methylprednisolone
therapy
X (standard
of care)
X (standard
of care)
X (standard
of care)
EPO/placebo
administration
X X X
AE reporting X X X X X X X X X§
Neurological examination,
EDSS¶
X X X X X X
Randomisation X
Refraction X X X X X X
OCT X X X X X
LCVA X X X X X X
HCVA X X X X X X
Continued
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Sample size calculation for RNFLT-G-12
In order to determine the required sample size at a
given signiﬁcance level α by means of a two-sided t test,
it is required to specify the clinically relevant difference
between treatment groups for which a power of 80% is
necessary, and assumptions on the SD of the primary
end point. We have based these assumptions on the
available studies published so far. For healthy or
unaffected fellow eyes, the RNFLT-G-12 ranges around
100 μm with a SD of less than 15 μm.13 16 28–31 After ON,
the following data have been published (RNFLT-G-12 in
micrometre with mean±SD, follow-up interval): 68.7
±18.8, 3 years after clinically isolated syndrome (CIS);29
85±17, >1 month after MS;16 65±17; <6 months after
CIS;30 84±12, 12 months after CIS31 and 83±18,
6 months after CIS.13 In the ON model, EPO reduced
retinal ganglion cell loss by 50%.5 Adapted to the
RNFLT-G-12, this effect would result in about 10 μm
RNFLT-G-12 difference which is in exact agreement with
the effect size observed in VISION PROTECT.6 These
investigations are the basis of our assumptions: For
patients with ON, a thinning of around 20% (15% to
25%) can be assumed in the placebo group. The abso-
lute values in the cited studies ranged from 11 to 26 μm.
In view of this range, a difference of 10 μm between
treatment groups is considered to be clinically relevant.
Our sample size calculation is based on the assumptions
mentioned above with an SD of 17 μm and a clinically
relevant difference between treatment groups (δ) of
10 μm with an α of 5% and a power of 80%. No adjust-
ment for multiple testing (two primary end points) is
necessary, as we are applying a hierarchical testing pro-
cedure. The resulting sample size is 47 per group and
94 patients in total, based on the two-sided t test. Since
the possibility of a proportion (5%) of non-evaluable
patients must be considered, 100 patients will be
randomised.
Sensitivity analysis of sample size calculation for
RNFLT-G-12
In the primary analysis, a regression model adjusting
for baseline RNFLT-G-12 of the fellow eye and stratify-
ing factors (eg, study site) will be applied. Less vari-
ability and hence higher power can then be expected
compared with the usual calculation via t test.
Using the two-sided t test for the sample size calcula-
tion therefore provides a conservative strategy. Table 2
provides sample size calculations for different
scenarios.
Table 2 displays resulting sample sizes per group
depending on different δ, SDs and power values. First,
we considered our assumptions of an expected differ-
ence of 10 μm with an SD of 17 μm as reasonable and
calculated the power depending on the sample size (n,
left table). Next, we varied the assumptions concerning
the difference between treatment groups (middle table)
and the SD assumptions (right table). Sample sizes per
group are listed and denoted as n.
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Sample size calculations by other authors have yielded
n=10032 and n=116 considering only the affected eyes
and n=72 considering the difference in RNFLT-G-12
between follow-up of the affected eye and baseline of
the fellow eye.13 All such calculations are based on time-
domain OCT data. Spectral-domain OCT, as used in this
trial with higher spatial resolution, is likely to provide
greater accuracy.
When the primary end point measurements of 50
patients are obtained, a blinded estimate of the SD will
be performed (total variance ignoring treatment assign-
ment).33 A revised sample size calculation based on the
new SD estimation will be obtained. No practically rele-
vant differences on the nominal signiﬁcance level have
been observed in the investigations of this procedure.33
Power calculations for LCVA
For LCVA as the other primary end point, less evidence
from published data is available so far. However, sample
size and power calculations have been performed for
LCVA in analogy to RNFLT-G-12. In patients with MS
and previous ON, mean LCVA >3 months after onset of
ON was 11.4 letters (SD 10.6) compared with 18.0 (SD
9.6) in MS non-ON eyes and 24.8 (SD 7.4) in healthy
controls.24 Median LCVA values of 15 in MS ON eyes, 24
in MS non-ON eyes and 32 in healthy controls were
reported in another publication.16 With 47 patients per
arm, 80% power is achieved with an assumed SD of 10.6
for a group difference of 6.2, corresponding to an
expected LCVA of 11.4+6.2=17.6 in the EPO arm.
Similarly, 47 patients per arm provide 70% power for δ
of 5.5 and expected LCVA of 16.9 in the EPO arm.
Therefore, the proposed sample size based on
RNFLT-G-12 provides sufﬁcient power for the second
primary outcome as well.
Randomisation and blinding
Blinding
The study medication will be prepared in a non-blinded
fashion by the pharmacy staff. The investigator who will
remain blinded to the patient’s assigned treatment
group will forward a copy of the completed randomisa-
tion form to the pharmacist. By means of a randomisa-
tion list provided by the sponsor, the pharmacist will
prepare the investigational product (verum or placebo)
according to the randomisation algorithm and will docu-
ment the corresponding patient number.
Randomisation methodology
To allow for ﬂexible randomisation independent of
ofﬁce hours, randomisation will be performed by using
sealed envelopes provided by the sponsor, which are
kept at the clinical trial sites. The randomisation code
will be generated by the Clinical Trials Unit, Medical
Center—University of Freiburg. Randomisation will be
performed stratiﬁed by trial site, in blocks of variable
size in a ratio of 1:1. Block size will be documented sep-
arately and will not be disclosed to the sites. The ran-
domisation code will be produced by validated
programmes based on the Statistical Analysis System
(SAS).
Statistical analysis
A detailed statistical analysis plan will be prepared. A
blind review of the data will be performed after the end
of the planned follow-up period without looking at the
randomised treatment for each patient. If the statistical
analysis plan contains any changes to the analyses out-
lined in the trial protocol, they will be marked as such,
and reasons for amendments will be given. All statistical
programming for analysis will be performed with the
SAS.
Definition of populations included in the analyses
The primary efﬁcacy analysis will be conducted accord-
ing to the intention-to-treat principle and will therefore
be based on the full analysis set. It preserves the treat-
ment allocation provided by randomisation and will be
as close as possible to the intention-to-treat ideal of
including all randomised patients. Patients without any
postrandomisation data will be excluded from the full
analysis set. For patients with missing data for the
primary end points, the last available outcome measure-
ment will be used for the calculation of the primary end
point.
The per-protocol population is a subset of the full ana-
lysis set and is deﬁned as the group of patients who
underwent the examinations required for the assessment
Table 2 Sample size calculations for different scenarios
n δ SD α Power n δ SD α Power n δ SD α Power
20 10 17 0.05 0.442 72 8 17 0.05 0.801 28 10 13 0.05 0.807
30 10 17 0.05 0.610 47 10 17 0.05 0.806 32 10 14 0.05 0.803
40 10 17 0.05 0.738 33 12 17 0.05 0.806 37 10 15 0.05 0.808
50 10 17 0.05 0.830 25 14 17 0.05 0.814 42 10 16 0.05 0.808
60 10 17 0.05 0.892 19 16 17 0.05 0.806 47 10 17 0.05 0.806
70 10 17 0.05 0.933 16 18 17 0.05 0.826 52 10 18 0.05 0.801
80 10 17 0.05 0.959 13 20 17 0.05 0.821 58 10 19 0.05 0.802
90 10 17 0.05 0.975 11 22 17 0.05 0.823 64 10 20 0.05 0.801
100 10 17 0.05 0.985 9 24 17 0.05 0.803 71 10 21 0.05 0.804
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of the end points at all times. Efﬁcacy analyses will be
performed in the per-protocol population for a sensitiv-
ity analysis. During the blind review of the data, it will be
decided which patients belong to the per-protocol
population.
Safety analyses will be performed in the safety popula-
tion. Patients in the safety population are analysed as
belonging to the treatment arm deﬁned by treatment
received. Patients are included in the respective treat-
ment arm, if they received at least one dose of trial
treatment.
Primary end point
As this study has two primary end points, a hierarchical
testing procedure will be applied in order to preserve
the type I error α=5%. RNFLT-G-12 will be tested ﬁrst.
Only in case a signiﬁcant difference between treatment
groups can be demonstrated, the test procedure for the
end point LCVA will be carried out. To formalise the
statistical approach, the following notation is used:
τEPO−τPLA: RNFLT-G-12 difference after 6 months
between EPO group and placebo group
θEPO−θPLA: LCVA difference after 6 months between
EPO group and placebo group.
The following two null hypotheses are tested hierarch-
ically at 5% level:
1. H0: τEPO−τPLA=0 vs H1: τEPO−τPLA≠0,
2. H0: θEPO−θPLA=0 vs H1: θEPO−θPLA≠0.
For both primary end points, the hypothesis will be
tested within a linear regression model, using the
outcome after 26 weeks as the dependent variable, and
with treatment assignment, study site and baseline meas-
urement (RNFLT-G-12 and LCVA, respectively) constitut-
ing independent variables (CPMP/EWP/2863/99).
RNFLT baseline measurements of the affected eye will
be subject to additional variation caused by swelling of
the optic disc. Therefore, baseline RNFLT-G-12 measure-
ments of the fellow eye will be used instead, as they are
an adequate covariate to reduce variation of the treat-
ment effect estimate. The deﬁnition of the ﬁrst primary
end point in the linear regression model is RNFLT-G-12
of the contralateral healthy eye at baseline minus
RNFLT-G-12 in the affected eye 6 months after random-
isation. The resulting treatment estimate from this
model is identical (apart from the sign) to the treatment
estimate resulting from a linear regression model with
the same covariates, but using RNFLT-G-12 in the
affected eye 6 months after randomisation instead as the
dependent variable. Within the linear regression model,
the treatment effect will be estimated and presented
with a two-sided 95% CI, and a two-sided test of the
treatment difference will be performed at the 5% signiﬁ-
cance level.
For patients with missing data for the primary end
points, the last available outcome measurement will be
used for the calculation of the primary end point. This
last-observation-carried-forward strategy seems reason-
able, as RNFLT deteriorates in the course of time and
95% of the expected RNFLT loss occurs at a mean of
3 months after the onset of symptoms.13 Rates of adverse
events leading to early termination of treatment are
expected to be very low because study medication will
only be given from days 1 to 3 of the trial. VISION
PROTECT had no drop-outs due to adverse events or
serious adverse events.6 As observations after 3 months
can be expected to be similar to observations after
6 months, it can be assumed that this procedure does
not notably affect variance estimation. Sensitivity ana-
lyses will be conducted by using multiple imputation
methods. The censoring distributions (time to drop-out)
will be compared for the randomised treatment groups.
Reasons for drop-out will be explored.
Secondary end points of efficacy
The secondary end points will be analysed as the
dependent variable in appropriate regression models.
MS and ON relapse rates will be estimated by the
Kaplan-Meier method, and Cox proportional hazards
regression models will be applied.
Safety parameters
All adverse events will be listed by trial site and patient and
displayed in summary tables. The total number of adverse
events, the minimum, maximum and mean number of
adverse events per patient, the total number of follow-up
days (number of days in the observation period), the
number of adverse events per follow-up day (total number
of adverse events divided by the total by the number of
follow-up days), the number of patients who had at least
one adverse event and the number of patients who
stopped treatment due to adverse events will be given.
Interim analysis
An interim analysis is planned for the time point when
50 patients have been randomised and followed up for
6 months. The interim report will describe patient
recruitment, treatment compliance as well as safety for
the patients in this period. Only blinded analyses will be
conducted in the interim analysis, since no major safety
problems are expected.
Additionally, a blinded estimate of the SD of the
primary end point will be calculated (total variance ignor-
ing treatment assignment).33 A revised sample size calcu-
lation based on the new SD estimation will be performed.
The results of the interim analysis will be reported only to
the independent data monitoring committee (DMC).
The DMC will give advice to the coordinating investiga-
tors concerning the further conduct of the trial.
Data monitoring committee
An independent DMC has been established. The func-
tion of the DMC is to monitor the course of the study
and if necessary to give a recommendation to the coord-
inating investigator and sponsor of the trial for discon-
tinuation, modiﬁcation or continuation of the study.
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Furthermore, the DMC may assist in the preparation of
Development Safety Update Reports.
Study progress
The recruitment period had started in September 2014
with opening of ﬁrst study centre. In March 2015, the
last of the currently running 13 study centres was initia-
lised. As of 5 February 2016, we have included a total of
51 patients.
DISCUSSION
ON is currently not effectively treated because immuno-
therapies available so far have only limited neuroprotec-
tive properties. ON offers several advantages for testing
neuroprotective agents as it represents a homogenous
disease with rapid and predictable neurodegeneration.
OCT allows for imaging of the proximal axon ﬁbres of
retinal ganglion cells, a subpopulation of central
nervous system neurons, without the presence of con-
founding myelin sheaths. Additionally, visual dysfunction
during and after ON can be precisely characterised by
functional and electrophysiological measurements. This
interdisciplinary study represents a conjoined effort of
neurologists and ophthalmologists and is designed as a
prospective, double-blind randomised clinical trial con-
ducted in different German University Medical Centers.
It substantiates a recent pilot trial by R Diem, which
showed a neuroprotective effect for EPO in ON.6 A posi-
tive outcome of TONE would not only improve the treat-
ment for ON but also have implications on therapy
development in MS, since RNFL atrophy is a surrogate
marker for neuronal degeneration in MS16 and corre-
lates with general brain atrophy.34
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